51ÔÚÏß

Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
Return to PRWeb homepage
  • News
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • 51ÔÚÏß
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • 51ÔÚÏß PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • RSS
  • 51ÔÚÏß
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • ·¡²Ô±¹¾±°ù´Ç²Ô­³¾±ð²Ô³Ù
    • Heavy Industry & Manufacturing
    • °Õ±ð±ô±ð³¦´Ç³¾³¾Â­³Ü²Ô¾±³¦²¹³Ù¾±´Ç²Ô²õ
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • RSS
  • RSS
  • RSS

Kyowa Hakko USA Receives U.S. Patent for Cognizin® Citicoline, Cementing Its Position as the Gold Standard Ingredient for Cognitive Health


News provided by

Kyowa Hakko USA

Oct 09, 2024, 09:00 ET

Share this article

Share toX

Share this article

Share toX

This patent further distinguishes Cognizin® as setting the standard for citicoline and ensures manufacturers who choose it are selecting the best option for their cognitive health products.
This patent further distinguishes Cognizin® as setting the standard for citicoline and ensures manufacturers who choose it are selecting the best option for their cognitive health products.

The issuance of the patent demonstrates Kyowa Hakko's commitment to delivering premium science backed ingredients.

NEW YORK, Oct. 9, 2024 /PRNewswire-PRWeb/ -- Kyowa Hakko USA, Inc., under the Cognizin® brand, is proud to announce the granting of a method-of-use patent for citicoline or its salts. The issuance of the patent demonstrates Kyowa Hakko's commitment to delivering premium science backed ingredients.

Patent Details:

"Receiving this patent underscores our dedication to innovation and excellence in nootropic ingredients," said Karen E. Todd, RD & Vice President of Global Brand Marketing at Kyowa Hakko.

Post this
  • Patent Title: ADMINISTRATION OF CITICOLINE TO IMPROVE COGNITIVE PERFORMANCE, ATTENTIONAL PERFORMANCE, AND MOTOR FUNCTION Patent Number: [US 12115181]

With this patent, product manufacturers in the food, beverage, and dietary supplement industries can now include citicoline in their formulations with more confidence than ever before. Manufacturers can reach new consumers knowing that they have IP protection. Cognizin® is committed to consumers receiving the cognitive benefits claimed on product labels when it is used consistent with clinical trial dosages, we believe it makes it the gold standard for citicoline ingredients.

"Receiving this patent underscores our dedication to innovation and excellence in nootropic ingredients," said Karen E. Todd, RD & Vice President of Global Brand Marketing at Kyowa Hakko. "The claims in this patent align with consumers' demand for exceptional ingredients in functional foods, beverages, and supplements." This is the fourth patent added to the existing lineup of Cognizin patents, which includes: US 11583546, US 11738037, US 10905705.

Cognizin® Citicoline extensive research over the past 30 years supports its ability to support mental energy, memory, and maintain healthy brain metabolism by supporting neurotransmitters. Unlike stimulants such as caffeine, Cognizin® delivers these benefits without causing jitters or crashes, making it an ideal ingredient for a wide range of products.

Key Benefits of Cognizin® Citicoline:

  • Efficacy: Supports both speed, accuracy, and attention in healthy individuals.
  • Optimal Dosage: 250mg to 500mg per day,
  • Versatile Application: Neutral in taste, water-soluble, and stable in heat, Cognizin® can be easily incorporated into various product formats, including beverages, foods, gummies, capsules, and candies.
  • Clean Label: Trusted by more than 200 functional foods, beverages, and dietary supplements, Cognizin® contains no food additives, artificial flavors, or preservatives.

"We were thrilled to be able to formulate with Cognizin® in our latest cognitive gummy, Matcha Mind," said Paula Sandoval, VP of Operations at Goli® Nutrition. "Their latest patent demonstrates its commitments to producing hiqh quality ingredients and the seamless formulation process."

This patent further distinguishes Cognizin® as setting the standard for citicoline and ensures manufacturers who choose it are selecting the best option for their cognitive health products. By incorporating Cognizin®, brands can confidently market their products that resonate with today's health-conscious consumers.

Functional food and beverage and supplement brands interested in formulating products for brain health can learn more about Cognizin® Citicoline at Cognizin.com.

About Cognizin® Citicoline
Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health. Citicoline is a brain-health nutrient. A patented form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, and attention. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure, and allergen-free. For more information on Cognizin®, visit Cognizin.com.

About Kyowa Hakko USA (Kyowa)
Kyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to improving the health and well-being of people worldwide by creating innovative solutions with science and nature. With cutting-edge research capabilities, Kyowa Hakko Bio is committed to developing unique ingredients supported by scientific evidence. For more information, visit kyowa-usa.com.

Media Contact

Maria Stanieich, Kyowa Hakko USA, 5514829968, [email protected],

SOURCE Kyowa Hakko USA

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact 51ÔÚÏß

Products

My Services
  • All News Releases
51ÔÚÏß Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025  US Inc.